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Platelet transfusion has been a vital therapeutic approach in patients with hematologic
malignancies for close to half a century. Randomized trials show that prophylactic platelet
transfusions mitigate bleeding in patients with acute myeloid leukemia. However, even with
prophylactic transfusions, as many as 75% of patients, experience hemorrhage. While
platelet transfusion efficacy is modest, questions and concerns have arisen about the
risks of platelet transfusion therapy. The acknowledged serious risks of platelet trans-
fusion include viral transmission, bacterial sepsis, and acute lung injury. Less serious
adverse effects include allergic and non-hemolytic febrile reactions. Rare hemolytic reac-
tions have occurred due to a common policy of transfusing without regard to ABO type. In
the last decade or so, new concerns have arisen; platelet-derived lipids are implicated in
transfusion-related acute lung injury after transfusion. With the recognition that platelets
are immune cells came the discoveries that supernatant IL-6, IL-27 sCD40L, and OX40L
are closely linked to febrile reactions and sCD40L with acute lung injury. Platelet trans-
fusions are pro-inflammatory, and may be pro-thrombotic. Anti-A and anti-B can bind to
incompatible recipient or donor platelets and soluble antigens, impair hemostasis and thus
increase bleeding. Finally, stored platelet supernatants contain biological mediators such
as VEGF and TGF-β1 that may compromise the host versus tumor response. This is partic-
ularly of concern in patients receiving many platelet transfusions, as for acute leukemia.
New evidence suggests that removing stored supernatant will improve clinical outcomes.
This new view of platelets as pro-inflammatory and immunomodulatory agents suggests
that innovative approaches to improving platelet storage and pre-transfusion manipulations
to reduce toxicity could substantially improve the efficacy and safety of this long-employed
therapy.
Keywords: platelets, transfusion, immune response, transfusion reaction, storage, thrombosis, bleeding
INTRODUCTION
Since their discovery, platelets have displayed a remarkable devel-
opment from a pro-thrombotic and pro-hemostatic cell fragment
to a surprisingly versatile immune-thrombotic cell. The plethora
of findings continues to surprise and excite at the same time.
In concordance, an old therapy, i.e., platelet transfusion, either
for prophylaxis or acute bleeding has been in transition as well.
Initially thought as an “easy fix” for thrombocytopenia, platelet
transfusions are now considered a double-edged sword at best.
Despite all the controversies, platelet transfusions are a clinical
necessity and do save lives every day worldwide. However, the
majority of platelet transfusions are administered for prophylactic
purposes, and for chronic conditions, rather than acute hemor-
rhage. It is presently unclear if platelet transfusions are effective
Abbreviations: NET, neutrophil extracellular trap; PMP, platelet microparticles; sPs,
soluble P-selectin.
in settings of acute hemorrhage. Moreover, the following ques-
tions are open and continue to evolve: Do platelet transfusions
work the way we think? What are the downsides to this therapy?
Some reports already highlight a pro-thrombotic side effect of
platelet transfusion, leaving the thrombocytopenic patient, who is
already at risk for bleeding with an increased risk of thrombosis
and bleeding at the same time.
PLATELETS – NOVEL FINDINGS IN IMMUNITY AND
INFLAMMATION
We briefly summarize a selection of the most relevant findings in
regards to an inflammatory and defensive role of platelets from
the recent literature.
Platelets are anucleate cell fragments, derived from megakary-
ocytes and circulate with an average number of 150,000–
300,000/µl in humans. Their role in thrombosis and hemostasis
has been well described. Their role in inflammation, however, was
www.frontiersin.org February 2015 | Volume 6 | Article 28 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stolla et al. The immunology of platelet transfusions
discovered only relatively recently and has constantly been evolv-
ing ever since. From an evolutionary perspective, platelets likely
originated from a versatile cell type with both strong hemosta-
tic and defensive cell properties (1, 2). Their role in hemostasis
is therefore closely intertwined with their sentinel and inflam-
matory properties. Activation of platelet surface receptors leads
to inside-out signaling, which is followed by integrin activation,
which in turn, is crucial for thrombus formation (3). In addition
to G-protein coupled receptors (mainly protease-activated recep-
tors, or PARs), platelets also possess immunoreceptor tyrosine-
based activation motif (ITAM), e.g., Fc-receptors, glycoprotein
VI, and C-type lectin-like receptor 2 (CLEC2). Fc-receptors allow
for immunoglobulin and immune complex binding, while GPVI
(the major collagen receptor) and CLEC2 are known to be impor-
tant for vascular integrity in inflammation (4). Toll-like receptors
(TLR) are present on platelets as well, although there are con-
flicting reports about their functionality (5–8). A recent report
indicated that platelets were able to discriminate between different
LPS isoforms by differential cytokine secretion by mononuclear
cells, including IL-6, TNF-α, and IL-8 (9). In addition, platelets
express the coxsackievirus and adenovirus receptor (CAR). Of
note, coxsackievirus 1 and 3 induced P-selectin exposure and
phosphatidyl serine exposure in platelets, albeit independently
of CAR. The presence of platelets led to lower coxsackievirus 1
and 3 titers, to less myocardial virus load and to better survival
in mice infected with the virus. To a similar conclusion came
authors of another recent paper, showing how platelets protect
the host during encephalomyocarditis virus (EMCV) infection
via TLR7. Platelet depletion led to reduced survival, and trans-
fusion of WT platelets into TLR7-deficient mice improved sur-
vival and was accompanied by a drop in platelet count (10).
Another virus, which has recently been described to interact with
platelets, is the H1N1 influenza virus. During infection with H1N1,
platelets show activation of their surface receptors, lipid mediator
generation, and release of microparticles. Interestingly, immu-
nized subjects showed circulating immune complexes of virus
and IgG, which were able to activate platelets via FcγRIIa. Alter-
natively, H1N1 virus was able to activate platelets via thrombin
generation (11).
Platelets express high-mobility group protein 1 (HMGB1) (12).
Upon activation, HMGB1 is translocated from the cytoplasm to
the outer plasma membrane. In its extracellular location, HMGB1
has been implicated in inflammatory, proliferative, and migratory
processes (13). TLR2, 4, 9, the receptor for advanced glycola-
tion end-products (RAGE) and Mac-1 have been described in
the inflammatory actions of HMGB1 (14–16), while ultimately
these signals lead to NF-κb activation. While HMGB1 has not
been investigated in the context of platelet transfusion, it is entirely
conceivable that HMGB1 accumulates during platelet storage and
triggers inflammatory sequela upon transfusion.
We and others have demonstrated that although platelets are
anucleate cell fragments they express an armamentarium of tran-
scription factors including the NF-κb transcriptional regulatory
system, Bcl-3, and PPARγ (17–22). The current concept is that
these factors act in non-transcriptional ways in platelets, e.g., by
modulating the response to activation, even though they act as
traditional transcription factors in megakaryocytes (17, 21).
Although platelets do not possess a nucleus, there is evidence
that platelets can synthesize IL-1β in substantial amounts upon
activation. In a resting state, platelets contain the pre-mRNA of
IL-1β. However, when activated, they synthesize pro-IL-1β pro-
tein, which is further processed and ends up as the mature form of
the cytokine IL-1β (23, 24). One of the earlier discoveries in platelet
biology was the tendency of platelets to “stick” to leukocytes when
activated and in generalized inflammatory conditions. All sub-
classes of leukocytes have been described to adhere to platelets
(25–27). However, the majority of studies describe myeloid leuko-
cytes as the platelet-binding partner. The interaction between
platelet and leukocyte mainly depends on the P-selectin – PSGL-1,
and fibrinogen – αIIbβ3, or directly to GPIb and αMβ2 (28).
The initial contact between leukocyte and platelet is established
via platelet P-selectin and leukocyte PSGL-1. On the molecular
level, P-selectin binds in a stereospecific manner to the N-terminal
region of PSGL-1, by recognizing a motif with tyrosine sulfate
residues, fucose, galactose, and sialic residues on a core-2 O-glycan
(29). Overall, the interaction between P-selectin and PSGL-1 has a
very rapid association/dissociation rate, facilitating the rapid cap-
ture, tethering, and rolling under high flow and shear conditions
(30). Of note, this initial step of tethering and rolling does not
require any leukocyte activation signals, but subsequent steps of
firm adhesion and transmigration require signaling events that
ultimately lead to integrin activation. Specifically, Nef-associated
factor 1 (Naf-1, downstream of PSGL-1) is phosphorylated by
Src-family kinase (SFK), and leads to Mac-1 (αMβ2) activation.
In addition, neutrophils show LFA-1 (αLβ2) activation, while
monocytes and lymphocytes show β1 and β2 activation (31, 32).
Integrin outside-in signaling via SFK then leads to phosphoryla-
tion of proline-rich tyrosine kinase 2 (Pyk2), which is followed
by a sustained leukocyte activation with stabilization of the inte-
grin bond and a delayed inflammatory response including NF-κb
activation. Furthermore, if circulating as heterotypic aggregates,
they can facilitate leukocyte deposition at sites of inflammation
and vascular injury and have been described in a plethora of
diseases (33–36).
Notably, platelets contain substantial amounts of CD40L (for-
mally known as CD154), a protein with a significant role in
T-cell-dependent isotype switching and generation of antibody
subclasses by B-cells. Platelets can stimulate neutrophils, T-cells,
and endothelial cells via CD40L (37–39). In addition to inter-
acting with leukocytes, platelets closely interact with endothe-
lial cells. Inflammatory conditions are usually accompanied by
a certain degree of vascular leakiness. Interestingly, thrombocy-
topenic patients usually do not bleed with platelet counts above
10,000/µl unless they develop inflammation. This contributory
role of platelets to vascular integrity seems to mainly depend on
platelet ITAM receptors (4, 40–42). In a similar way, platelets seem
to protect the vasculature in tumors and prevent bleeding inside
of tumors (43, 44). Surprisingly, platelets have also been found to
enhance vascular permeability during inflammation, perhaps due
to their secretion of VEGF, serotonin, and other similar factors.
These seemingly contradictory results might reflect model, species,
and site-specific differences, but it might also depend on a differen-
tial release of mediators, specifically serotonin has been shown to
be crucial for the induction of vessel permeability by platelets (45).
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How the differential contribution to vessel integrity and leakiness
is regulated in vivo remains to be investigated. Examining vas-
cular integrity during dengue virus infection, Hottz et al. found
that platelets contribute to vascular leakage by releasing IL-1β-
rich microparticles after assembly of nucleotide-binding domain
leucin-rich repeat containing protein (NLRP3), and are thus likely
to contribute to hemorrhage frequently observed during infection
with this virus (46). Other virus-induced hemorrhagic fevers also
critically involve platelets (47). Recent studies also highlight the
ability of platelets and platelet-like particles to transfer microRNA
to leukocytes and endothelial cells. Even though this has not been
shown to be the case in an inflammatory setting, it is an inter-
esting mechanism to transfer “long distance” information and
contribute to vascular homeostasis (48). An intriguing recent study
by Massberg et al. suggested that platelets serve as “first sensors”
for endothelial damage and potential invaders. Platelets adhered
to and activated neutrophils, which in turn released nucleosomes
and serine proteases in order to trigger the intrinsic and extrinsic
coagulation pathway. This localized promotion of thrombosis by
platelets and neutrophils in order to trap invaders in the micro-
circulation is a novel example of how closely intertwined innate
defense mechanisms and thrombotic processes are (49, 50).
One of the most striking recent findings is how neutrophils pro-
duce extracellular traps, or “neutrophil extracellular traps (NETs)”
in order to cause thrombosis and thereby trap invading microbes.
While neutrophils are the major inducer of NETs by ejecting their
nucleus, there is emerging evidence that platelets assist neutrophils
in this process: plateletβ-defensin-1 released after stimulation with
Staphylococcus α-toxin was found to be critically involved in the
formation of NETs under flow conditions in vitro and in vivo
(51). Earlier, an elegant study by Clark et al. showed that TLR4
on platelets binds to circulating LPS and mediates neutrophil–
platelet binding with subsequent neutrophil activation and NET
formation in mice and humans. The authors were able to show
that NET formation helped trapping bacteria. Similar to the study
mentioned above by Massberg et al., platelets function as a “sen-
sor” for circulating LPS and facilitate neutrophil activation (52).
Of note, platelets were also critically involved in NET formation
in a mouse model of transfusion-related acute lung injury (53,
54). A somewhat under-recognized cell organelle in platelets has
recently been shown to contribute to the inflammatory response
by platelets: by releasing mitochondria, either free or coated by
microvesicles, they provided the substrate for secreted phospholi-
pase A2-IIa (PLA2-IIa), which in turn produces lysophospholipids,
fatty acids, and mtDNA to activate leukocytes (55).
PLATELET STORAGE AND INFLAMMATION
Prolonged storage leads to changes in platelets mostly associated
with platelet activation. Contents of the alpha granules are secreted
which leads to a gradual increase in P-selectin and CD40L mem-
brane expression. Consistently, the number of platelets attached to
leukocytes increases over time during storage (56). A substantial
amount of P-selectin and CD40L are shed into the plasma as solu-
ble P-selectin (sPS) and sCD40L, respectively (57, 58) (Figure 1).
CD40L and its interaction with neutrophils and endothelial
cells have been implicated in the development of non-antibody-
mediated transfusion-associated acute lung injury (TRALI) (39).
Of note, platelets act in concert with T-cells to mediate B-cell
stimulation and function as a “first wave” of B-cell activation (37).
Specifically, after a 3-day incubation with platelets, B cells showed
an increased production of IgG1, IgG2, and IgG3, but not IgG4,
IgA, or IgM (37). Interestingly, activation of dendritic cells by
platelets has proven to be independent of sCD40L. While platelets
do stick to dendritic cells, dendritic cell activation is mediated by
nucleotides like ADP and ATP (59). Platelet CD40L has also been
involved in host defense against Listeria monocytogenes in a mouse
model (60). In addition to its role in inflammation, platelet CD40L
has also been implicated in more traditional roles of platelets
such as thrombus formation and thrombus stabilization (61). In
addition to P-selectin and CD40L, multiple other platelet alpha
and dense granule substances are found in the supernatant: e.g.,
β-thromboglobulin, platelet factor 4, and serotonin (62).
Stored platelets also exhibit an increase in phosphatidylser-
ine (PS) exposure (Figure 1), which can be assessed via annexin
V binding. Of note, the degree of platelet activation does not
correlate with P-selectin expression, platelet count increment, or
function in vivo. P-selectin-expressing platelets that were trans-
fused into primates and rabbits rapidly lost their surface P-selectin
but continued to function and to circulate in vivo (63–65).
Platelet microparticles (PMP) are released from platelets upon
activation or apoptosis. Platelet concentrates contain PMPs in the
supernatant, reflecting activation during collection, and/or storage
(Figure 1). Apheresis collection is associated with less PMP for-
mation when compared to platelets separated from whole blood
donations (66, 67). PMPs have been shown to be critically involved
in inflammatory conditions like rheumatoid arthritis (68). Infu-
sion of activated platelets and microparticles causes early ather-
osclerotic lesions (fatty streaks) and exacerbate atherosclerosis in
mice and diabetic patients (69–71). Furthermore, PMPs enable
platelets to transport RNA, cytokines, or chemokines to other
cells and tissues, as they are small enough to exit the circulation
and to enter the surrounding tissues. This has been shown for
RANTES (72), IL-1α (68), IL-1β (24, 73), PPARγ (74), retinoid
X transcription factor (74), and CD40L (75, 76), albeit not under
transfusion conditions. Human cytomegalovirus (HCMV) acti-
vates platelets via TLR2 and triggers ADP release and subsequent
platelet leukocyte aggregate formation in vitro and in vivo, which
might explain how this virus might contribute to atherosclerotic
lesion formation (77).
We were recently able to show that the composition of
microparticles can be altered by genetic engineering. Using lentivi-
ral technology, we introduced green fluorescent protein (GFP) and
increased PPARγ expression in megakaryocytic cell lines and pri-
mary megakaryocytes. Platelets and microparticles generated by
modified megakaryocytes were internalized by a monocytic cell
line and altered the expression of a target protein of PPARγ. This
is a potentially useful tool in altering and investigating transcel-
lular communications (78). To what extend PMP contribute to
the hemostatic properties of platelet transfusions has not been yet
investigated. Moreover, PMPs function as messengers to convey
pro-inflammatory information to endothelial cells and leuko-
cytes. No study has investigated the pro-inflammatory role of
PMPs after transfusion yet, but it seems likely that there are
some systemic effects to the recipient. Stored platelets also contain
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FIGURE 1 | Unwanted passengers and events during platelet storage:
Besides platelets, platelet concentrates contain “unwanted passengers”
in the form of soluble mediators in the supernatant (in the case of
unwashed platelet concentrates – which are still the routine product
in virtually all US hospitals) and leukocytes (in the case of non-
leukoreduced platelet concentrates – which are still an available
product in some US hospitals). The supernatant (red background) contains
substances which are secreted or shed into the plasma during storage
containing soluble mediators, like sCD40L, PDGF, or sP-selectin. In addition,
cytokines and cell fragments can be found. The platelet themselves (yellow
background) change during storage. They become hyporesponsive (not
depicted), and degranulate with increased expression of alpha granule
contents (e.g., P-selectin). Platelets express ABO antigens, which lead to
suboptimal results and complications if transfused into ABO-unmatched
recipients. A marker for platelet activation is platelet leukocyte aggregate
formation (white background). With prolonged storage, the number of platelet
leukocyte aggregates increase. Leukocytes in the stored bag (gray
background) release cytokines, which can induce febrile transfusion reactions.
Passenger leukocytes lead to sensitization to HLA antigens with subsequent
refractoriness.
minute fragments of leukocytes that have been involved in HLA-
sensitization and platelet refractoriness in pre-clinical studies (79)
(Figure 1).
Adding some clinical relevance to the aforementioned pre-
clinical in vitro and lab findings, we were able to show that washing
red cells and platelets (i.e., removing the supernatant) is associated
with less inflammatory response in high-risk pediatric populations
compared to non-washed platelet transfusions (80). Furthermore,
the patients in the study-arm needed fewer transfusions and there
was a trend to lower mortality in the study-arm (washed units).
Larger clinical trials are needed to determine if this finding is
clinically significant (80).
TRANSFUSION REACTIONS AND IMMUNOMODULATION
Although platelet transfusions are generally well-tolerated, they
cause more transfusion reactions than any other blood prod-
uct (81). The adverse events range from simple allergic reactions
to severe anaphylactic reactions, febrile-non-hemolytic reactions,
transfusion-associated sepsis, and TRALI. Several strategies have
been shown to reduce the rate of transfusion reactions, e.g., leuko-
cyte reduction, washing, and ABO matching. As described above,
stored platelets release sCD40L and accumulate CD40L on their
surface. In fact, platelet concentrates from apheresis and whole
blood collection demonstrated the highest sCD40L concentrations
compared to all other blood products (39). Platelet concentrates
involved in TRALI had significantly higher sCD40L levels com-
pared to uninvolved ones. In vitro sCD40L was able to prime
the PMN oxidase rapidly suggesting that sCD40L could be criti-
cally involved in non-antibody-mediated TRALI (39). But, its role
might not be limited to that; earlier data from our group sug-
gested that sCD40L could induce febrile transfusion reactions by
activating cyclooxygenase-2 and thereby producing prostaglandin
E2 (82). Of note, the concentrations that were required to produce
PGE2 in vitro are easily met and even exceeded by one order of
magnitude after transfusion of unwashed platelets. In addition,
cytokine accumulation (e.g., IL-1β, IL-6, IL-27) and accumula-
tion of soluble OX40 ligand in the stored platelet bag has been
shown to contribute to febrile non-hemolytic reactions (83, 84)
(Figure 1). Washing and leukoreduction was protective and helped
to reduce the incidence of febrile transfusion reactions (85–87). In
addition to sCD40L, cytokines, and sPS, platelet-derived growth
factor (PDGF) accumulates during platelet storage (88). Moreover,
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other growth factors like VEGF, FGF-2, and TGF-β1 have been
shown to accumulate during platelet storage (89–91) (Figure 1).
Upon transfusion into patients with (hematologic-) malignancies,
these growth factors may promote cancer growth and antago-
nize growth factor-targeted therapies (90). Overall, there is good
reason to believe that the number of described soluble media-
tors is not complete; as a recent study showed the presence of
1048 proteins in the supernatant, including 69 membrane proteins
(10 had been shown to be shed from platelets before). However,
this data warrants further validation under storage conditions
since platelets were activated with agonists instead of activating
them by prolonged storage (92). We previously investigated the
platelet proteome under storage conditions, using mass spectrom-
etry and found that 117 proteins changed during storage condi-
tions. Notably, 22 out of 117 proteins were previously described
in platelets and two-thirds of these 22 were associated with alpha
granules, supporting degranulation as one of the major events
during storage (93).
In an intriguing study, Yazer et al. investigated if a febrile
non-hemolytic transfusion reaction renders the patient more sus-
ceptible for the development of alloantibodies to subsequent red
blood cell products, and found a significantly higher rate of sensi-
tization in the study-arm (94). This result corroborated recent
findings in animal models (95, 96) and is presumably due to
cytokines in the platelet unit that are high enough to induce
a febrile transfusion reaction and generate a humoral immune
response which predisposes the recipient to more effective anti-
body production (97). The idea that transfusions could alter the
immune system of the recipient other than through alloimmu-
nization stems from the discovery that allogeneic transfusions
enhanced kidney graft acceptance in transplant recipients (98).
Shortly afterwards, an association between colorectal cancer recur-
rence and transfusion was noted and confirmed in retrospective
studies (99–101). In concordance was another subsequent finding
that transfusions are associated with infections perioperatively in
cancer patients (102). Although all of the above mentioned ini-
tial work on transfusion-mediated immunomodulation was done
on red blood cell transfusions, it is likely that soluble mediators
that accumulate in platelet concentrates have an immunomodula-
tory effect upon transfusion into the recipient as well. Specifically,
sCD40L and similar mediators could alter host defense in a way
that tumor defense is impaired by shifting the immunity toward
a type-2 immune function (103, 104). Our group demonstrated
that sCD40L stimulates PGE2 production and induces COX-2 (58,
82, 105, 106). Another possible mechanism may be that sCD40L
functions as a proliferation and survival factor for the circulat-
ing leukemic cells. It is likely that washing platelet concentrates
before transfusions improves survival in leukemic patients (107,
108). We were recently able to replicate our previous findings in
younger patients with acute myeloid leukemia with a striking sur-
vival benefit of almost 100% in patients with favorable risk AML
on a washed transfusion protocol and a short-term mortality of
nearly 0% in patients with any type of AML in the treatment
group (washed protocol, unpublished observations). Washing the
platelet concentrate is an inexpensive and relatively easy way to get
rid of the supernatant. It goes along with a mild activation and
a minor loss of platelet numbers prior to transfusion. However,
these modest downsides are disproportionate as compared to the
potential benefits to patients in terms of survival.
Interestingly, the rate of TRALI is highest in platelet trans-
fusions. Although it has never been convincingly demonstrated
that transfused platelets are causally related to the development
of TRALI, a recent discovery linked recipient platelets to the
pathogenesis in antibody-mediated TRALI. Aspirin treatment and
platelet depletion prevented TRALI in a mouse model (54). Fur-
thermore, two papers linked NETs to the pathogenesis of TRALI
and one of them linked the occurrence of NETs directly to platelets
(53, 109).
ABO MATCHING FOR PLATELET TRANSFUSIONS
The ABO blood group system is still the most important system
in transfusion medicine since it was first discovered by Karl Land-
steiner roughly a century ago. ABO antigens are both integral to
and passively adsorbed onto the red blood cell surface. The discov-
ery that platelets also express ABO antigens was made in the 1950s
(110). More recently, they have been localized on integrins αIIbβ3
and α2β1 (111, 112). One of the earliest clinical discoveries was
that non-ABO-matched platelets transfusions yield a lower platelet
count increment (113). This was further substantiated in multiple
randomized and observational studies; in addition ABO-matched
platelet transfusion protected better from bleeding and led to less
frequent refractoriness (114–116). In vitro, co-incubation of A, B,
or AB platelets with O plasma with differing titers of anti-A and
anti-B inhibited platelet aggregation and was also associated with
other anticoagulant properties, delivering a potential explanation
for the reduced hemostatic activity of non-ABO-matched platelet
transfusions (117). The lower platelet increment is speculatively
due to clearance of antibody-coated platelets and platelets coated
with immune complexes by phagocytic cells. We showed previ-
ously, that circulating ABO immune complexes that were isolated
from patients after non-ABO-matched transfusion were able to
adhere to platelets via the Fc-receptor and complement recep-
tors, cC1q and gC1q. In addition, in vitro formed ABO immune
complexes showed the same ability to bind platelets via the afore-
mentioned receptors. Inhibition of the receptors with blocking
antibodies reduced the amount of bound immune complexes by
67–99%. Together these findings provide an additional poten-
tial mechanism for platelet clearance after non-ABO-matched
transfusion and overall for the importance of ABO-matched
transfusions clinically (118).
In a cohort trial investigating the effect of ABO matching
platelets in patients undergoing cardiac surgery, we showed that
patients who received at least one ABO-mismatched pool of
platelet had significantly longer hospital stays, more days of
fever, and more RBC transfusions. Notably, recipients of ABO-
identical platelets had one-quarter the mortality, fewer mean days
of antibiotics and hours in the ICU than patients receiving ABO-
mismatched transfusions. Maybe due to the smaller number of
patients, these latter differences were not significant (119). Our
institution switched to universal ABO-matched platelet and cryo-
precipitate transfusion in 2005, and this approach led to improved
clinical outcomes and reduced transfusion requirements in sur-
gical patients (120). Furthermore, this approach has also proven
feasible from a blood management and administrative standpoint
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(121). Table 1 summarizes all findings from trials that were per-
formed by our group, at our institution with regards to ABO
matching and platelets transfusions.
ALLOIMMUNIZATION TO HLA
Patients who receive frequent platelet transfusions sometimes
become less responsive to platelet transfusion, a phenomenon
termed “refractoriness.” There are immune-mediated mecha-
nisms of platelet refractoriness and non-immune-mediated mech-
anisms. Overall, the non-immune platelet removal is more com-
mon than immune-mediated removal (122). However, in light of
the focus of this review article, we will focus on the immune-
mediated mechanisms. The most common reason to develop
immune-mediated platelet refractoriness is the development of
antibodies to foreign HLA A, B (class I MHC), which are expressed
on platelets and most other cell types, or the development of
platelet-specific antibodies. Interestingly, in case of the sensitiza-
tion to HLA antigens, transfusion of leukocyte containing blood
products is associated with a higher rate of immunization, and
consistently, universal leukoreduction leads to a significant reduc-
tion in platelet refractoriness (123) (Figure 1). This along with
others lead to the conclusion that transfusing a small amount of
leukocytes with red blood cells or platelets is more immunogenic
than the transfused platelets themselves. Our institution’s pol-
icy is to transfuse only leukoreduced and ABO-identical platelets,
and our internal data suggest that this leads to fewer incidences
of platelet refractoriness (<1% of patients). One potential solu-
tion when alloimmunization has occurred and refractoriness is
evident is to expend the money necessary and engage in the time-
consuming process of finding an HLA-matched donor. This can
be facilitated by HLA-matching or by a test that determines the
antibody specificity and selects donors based on their lack of the
corresponding antigens (124).
PLATELET TRANSFUSION AND THROMBOSIS
Inflammation and thrombosis are closely intertwined; it is there-
fore conceivable that platelet transfusions not only lead to inflam-
mation, but also thrombosis. Indeed, there is evidence, mainly
coming from an observational study, that transfusions are asso-
ciated with thrombosis. A retrospective study investigated the
associations between transfusions and venous thromboembolism,
arterial thromboembolism, and mortality in hospitalized patients
with cancer. All three outcomes were significantly more common
in patients that received platelet transfusion (125). However, more
studies, preferably randomized, controlled trials are needed to
show this association is indeed causal. More data is available for
red blood cell transfusions (126, 127), while overall clinical data
on this subject is still rather scarce.
It is one of the issues of platelet transfusions that the hemostatic
potential of the stored platelets decrease over time in the storage
bag. On the other hand, the amount of soluble pro-inflammatory
and pro-thrombotic mediators in the supernatant increases. These
mediators presumably partially compensate for the loss of platelet
function, but it is plausible that they contribute to thrombosis
as well. Platelet-derived microparticles and sCD40L have been
shown to be involved in thrombosis under pre-clinical, experi-
mental conditions and are most likely amongst the culprits that
mediate thrombosis (128–131).
Overall it appears, as if fresher platelets (<3 days of storage)
are preferable due to reduced cytokine load and are likely less
Table 1 | Studies investigating the role of ABO-group matching in platelet transfusions.
Author Study type/question Result Year Journal Reference
Heal et al. In vitro study investigating the role of
circulating immune complexes after
ABO-non-identical transfusion
Circulating immune complexes adhere to platelets via
Fc-receptor and complement receptors and provide a
potential mechanism for platelet clearance
1996 Vox sanguinis (118)
Blumberg et al. Retrospective cohort-study investigating
patients undergoing cardiac surgery
Patients who received ABO-mismatched platelets had
a longer hospital stay, more fever, and more RBC
transfusion. Furthermore, there was a trend toward a
75% reduction in mortality with ABO-identical platelets
2001 Transfusion (119)
Refaai et al. Retrospective analysis of non-ABO-
identical platelet transfusion and the
effect on transfusion requirements and
other clinical parameters
ABO-identical transfusions might lead to lower
transfusion requirements and better clinical outcome
2011 Vox sanguinis (120)
Henrichs et al. Feasibility trial, designed to answer if
uniform ABO-identical platelet transfusion
is doable in a tertiary care hospital setting
97% of patients received ABO-identical platelets.
There was an unexpected reduction in febrile and
allergic reactions. In addition, there was a reduction in
RBC alloimmunization and HLA platelet requirements
2012 Transfusion (121)
Refaai et al. In vitro study investigating the effect of
anti-A and anti-B on platelet function and
clot formation
Anti-A and anti-B inhibit platelet aggregation and
reduce clot formation in various in vitro assays
2013 Transfusion (117)
The table summarizes the in vitro and clinical studies by our group at the University of Rochester investigating the role of the ABO blood group system in platelet
transfusions.
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pathogenic. More clinical studies are needed to evaluate the hemo-
static improvement and/or impairment, as well as the thrombotic
risk as a function of storage time.
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